Aytu BioScience (NASDAQ: AYTU) reported Q2 EPS of ($0.89), versus ($1.78) reported last year. Revenue for the quarter came in at $1.05 million versus the consensus estimate of $1.3 million.

• Total revenue for the second quarter of 2018 was $1,050,000 compared to revenue of $794,000 for the same period last year, an increase of 32%. Natesto and MiOXSYS comprised the majority of sales in the second quarter of 2018. Product sales in the same quarter of 2017 were mostly comprised of ProstaScint and Primsol, a product that was divested in late fiscal 2017.
• Operating expenses for the second quarter of 2018 were $5,045,000, which was in line with the same quarter last year.
• Cash used in operations for the quarter was $3,101,000, down 26% from the first quarter of 2018.
• Cash and cash equivalents totaled approximately $4,000,000 as of December 31, 2017.

For earnings history and earnings-related data on Aytu BioScience (AYTU) click here.